Nektar Therapeutics
NKTR
158 hedge funds and large institutions have $824M invested in Nektar Therapeutics in 2025 Q3 according to their latest regulatory filings, with 67 funds opening new positions, 44 increasing their positions, 27 reducing their positions, and 20 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
292% more capital inflows, than outflows
Capital inflows: $313M | Capital outflows: $79.7M
235% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 20
63% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 27
41% more funds holding
Funds holding: 112 → 158 (+46)
14.38% more ownership
Funds ownership: 61.72% → 76.1% (+14%)
37% less call options, than puts
Call options by funds: $47.7M | Put options by funds: $75.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
+$42.3M |
| 2 |
Morgan Stanley
New York
|
+$28.4M |
| 3 |
Farallon Capital Management
San Francisco,
California
|
+$26.2M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$13M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$11.1M |
| 3 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$9.6M |
| 4 |
TCG Crossover Management
Palo Alto,
California
|
-$6.89M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.73M |
NKTR Hedge Fund Activity: Q3 2025 in Review
158 of the 7,661 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2025, worth a combined $824M — up 316% from $198M a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new NKTR positions and 20 closed out — a net gain of 47 holders — while 44 added to existing stakes and 27 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $42.3M. The largest seller was Acadian Asset Management, cutting an estimated $13M.
- 158 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2025, up from 112 in Q2 2025.
- Funds reported $824M of Nektar Therapeutics stock for Q3 2025, up 316% quarter-over-quarter.
- 67 funds opened new Nektar Therapeutics positions in Q3 2025 and 20 closed out, a net change of +47 holders.
- The largest Nektar Therapeutics buyer in Q3 2025 was BVF Inc, an estimated $42.3M added.
- The largest Nektar Therapeutics seller in Q3 2025 was Acadian Asset Management, an estimated $13M sold.
Based on aggregated 13F filings for Q3 2025.